glutathione news philippines Unlocking the Power of Emothion® for Radiant Skin in Southeast PH dermatologists warn public against

Sermorelin vs BPC 157 is a common comparison in peptide therapy because these compounds are used for very different goals

[DOI] [PMC free article] [PubMed] 63.McIntosh CH, Widenmaier S, Kim S-J

The seven (7) peptide bulk drug substances expected to be considered by the PCAC in July, together with the uses identified for evaluation, are: July 23, 2026 : BPC-157 (free base and acetate): ulcerative colitis KPV (free base and acetate): wound healing and inflammatory conditions Thymosin Beta-4, Fragment (LKKTETQ)(TB-500) (free base and acetate): wound healing MOTs-C (free base and acetate): obesity and osteoporosis July 24, 2026 : Emideltide (DSIP) (free base and acetate): opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate): cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate): insomnia The peptide substances scheduled for consideration at the July 23-24, 2026, PCAC meeting are among those identified for removal from Category 2

4.4 Nanotherapeutics Cancer therapies targeting ferroptosis and cuproptosis are current research hotspots, but they still face numerous challenges

Notch signaling regulates immune responses in atherosclerosis